Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ALXN2050 in Renal Impairment
NCT04623710Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vemircopan in paroxysmal nocturnal hemoglobinuria (PNH) (4 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Area Under The Concentration-time Curve From Time 0 To The 12-hour Time Point, Area Under The Concentration-time Curve Calculated To The Last Observable Concentration and 2 more. Started Jul 2021; status: completed.
02
Drugs
vemircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04623710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623710.